Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 29-36

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biopharmaceutical; Biosimilar; Cost effectiveness; Economic evaluation; Reimbursement

Indexed keywords

BETA INTERFERON; BIOLOGICAL PRODUCT; BIOSIMILAR; ETANERCEPT; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HUMAN INSULIN; INFLIXIMAB; INSULIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RITUXIMAB; SILDENAFIL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BIOEQUIVALENCE; BIOTECHNOLOGY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; EXPIRATION DATE; FEBRILE NEUTROPENIA; HEALTH CARE COST; IMMUNOGENICITY; OUTCOME ASSESSMENT; PATENT; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 79952973241     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S12494     Document Type: Article

References (41)

1. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late- Stage biopharmaceutical pipeline. Am J Manag Care. 2003;9 Suppl 6: S124-S135.
2. Young FE. Biotechnology: the view from the FDA. Health Matrix. 1986;4(3):10-15.
3. Zuniga L, Calvo B. Biosimilars-the way forward. Hosp Pharm Europe. 2010;50:33-34.
4. Cohen M, Morrow T, Penna P. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies. Am J Manag Care. 2006;12 Suppl 2:S24-S37.
5. Simon F. Market access for biopharmaceuticals: new challenges. Health Aff (Millwood). 2006;25(5):1363-1370.
6. European Medicines Agency. Guideline on Similar Biological Medicinal Products. 2006. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed December 6, 2010.
7. United States Congress. Patient Protection and Affordable Care Act. 2010. Available from:http://www.opencongress.org. Accessed December 6, 2010.
8. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies. 2010. Available From http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf. Accessed December 6, 2010.
9. European Medicines Agency. Concept Paper on Similar Biological Product Containing Recombinant Interferon Beta. European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089210.pdf. Accessed December 6, 2010.
10. European Generic Medicines Association. Vision 2015. The EGA's Thoughts on How to Improve the Legal and Regulatory Framework for Generic and Biosimilar Medicines. 2010. Available from: http://www.egagenerics.com/doc/EGA_Vision_2015.pdf. Accessed December 6, 2010.
11. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
12. Perleth M, Jakubowski E, Busse R. What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Policy. 2001;56(3):235-250.
13. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411-419.
14. Roger SD, Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther. 2008;33(5):459-464.
15. Stewart A, Aubrey P, Belsey J. Addressing the health technology Assessment of biosimilar pharmaceuticals. Curr Med Res Opin. 2010; 26(9):2119-2126.
16. European Medicines Agency. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Guidance on Similar Medicinal Products Containing Somatropin. 2006. Availablefrom: http://www.ema.europa.eu/pdfs/human/biosimilar/9452805en.pdf. Accessed December 7, 2010.
17. De Mora F, Torres R. Biotechnology-derived medicines: what are they? A pharmacological and a historical perspective. J Generic Med. 2010; 7(2):145-157.
18. Hughes DA. Biosimilars: evidential standards for health technology assessment. Clin Pharmacol Ther. 2010;87(3):257-261.
19. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines- similarities, differences and some implications. Value Health. 2001;4(3): 225-250.
20. Scottish Medicines Consortium. Epoetin Zeta. Scottish Medicines Consortium; 2010. Available from: http://www.scottishmedicines.org.uk/smc/6094.html. Accessed December 7, 2010.
21. de Joncheere K, Rietveld AH, Huttin C. Experiences with generics. IntJ Risk Safety Med. 2002;15:101-119.
22. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43(4):462-469.
23. Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010;49: 33-34.
24. Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood). 2006;25(5):1291-1301.
25. Long M, Trout J, Akpinar P. Biosimilars: HGH to TNFS, how will payers respond? PriceSpective. 2009 Oct 26.
26. European Generic Medicines Association. EGA Handbook on Biosimilar Medicines. 2010. Available from: http://www.egagenerics.com/bio-handbook.htm. Accessed December 7, 2010.
27. Oldham T. Strategies for entering the biosimilar market. In: Oldham T, editor. Biosimilars-Evolution or Revolution? London, UK: Biopharm Knowledge Publishing; 2006.
28. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007;23(1):105-116.
29. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin. 2007;23(10):2467-2476.
30. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715-724.
31. Scottish Medicines Consortium. Ratiograstim. 2009. Available from: http://www.scottishmedicines.org.uk/files/filgrastim_Ratiograstim_FINAL_Oct_2009_Revised_031109.doc_for_website.pdf. Accessed December 8, 2010.
32. National Institute for Health and Clinical Excellence. Human Growth Hormone (Somatropin) for the Treatment of Growth Failure in Children (Review of NICE Technology Appraisal Guidance 42). 2010. Available from: http://guidance.nice.org.uk/TA188. Accessed December 8, 2010.
33. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551-556.
34. Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing Agreements on pricing, promotion, and net health benefits. Value Health. 2009;12(5):838-845.
35. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19(11):1103-1109.
36. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146(4):473-481.
37. Raftery J. Review of NICE's recommendations, 1999-2005. BMJ. 2006;332(7552):1266-1268.
38. Health Care Insurance Board. Richtlijnen voor farmaco-economisch onderzoek (Guidelines for Pharmaco-Economic Research). Amstelveen, The Netherlands: Health Care Insurance Board; 1999.
39. PHARMAC. Prescription for Pharmacoeconomic Analysis: Methods for Cost-Utility Analysis. Auckland, NZ: PHARMAC; 2007.
40. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178.
41. IMS Health. Midas Database. London, UK: IMS Health; 2008.